RSS-Feed abonnieren
DOI: 10.1055/a-1233-3582
Saliva versus Plasma Therapeutic Drug Monitoring of Gentamicin in Jordanian Preterm Infants. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary Excretion Classification System
Funding: This research was funded by Petra University fund # 4–2019.![](https://www.thieme-connect.de/media/drugres/202010/lookinside/thumbnails/2020-06-2052_10-1055-a-1233-3582-1.jpg)
Abstract
Gentamicin has proven to be a very successful treatment for bacterial infection, but it also can cause adverse effects, especially ototoxicity, which is irreversible. Therapeutic drug monitoring (TDM) in saliva is a more convenient non-invasive alternative compared to plasma. A physiologically-based pharmacokinetic (PBPK) model of gentamicin was built and validated using previously-published plasma and saliva data. The validated model was then used to predict experimentally-observed plasma and saliva gentamicin TDM data in Jordanian pediatric preterm infant patients measured using sensitive LCMS/MS method. A correlation was established between plasma and saliva exposures. The developed PBPK model predicted previously reported gentamicin levels in plasma, saliva and those observed in the current study. A good correlation was found between plasma and saliva exposures. The PBPK model predicted that gentamicin in saliva is 5–7 times that in plasma, which is in agreement with observed results. Saliva can be used as an alternative for TDM of gentamicin in preterm infant patients. Exposure to gentamicin in plasma and saliva can reliably be predicted using the developed PBPK model in patients.
Key words
antibacterial drugs, pharmacology, pharmaceutics, SECS - TDM - Gentamicin - Pk-Sim - PBPK - Preterm infantsPublikationsverlauf
Eingereicht: 05. April 2020
Angenommen: 01. August 2020
Artikel online veröffentlicht:
02. September 2020
© 2020. Thieme. All rights reserved.
© Georg Thieme Verlag KG
Stuttgart · New York
-
References
- 1 Abou-Zeid AA, Eissa AI, Salem HM. Mode of action of Gentamicin antibiotics produced by Micromonosporapurpurea. ZentralblattfürBakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. ZentralblBakteriolNaturwiss 1978; 133 (04) 362-368
- 2 Coutinho AGG, Biscaia SMP, Fernandez R. et al. The aminoglycoside antibiotic Gentamicin is able to alter metabolic activity and morphology of MDCK-C11 cells: A cell model of intercalated cells. Braz J Med Biol Res 2018; 51 (10) 1-7
- 3 Bethesda MD. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK547852/
- 4 Pacifici GM, Marchini G. Clinical pharmacokinetics of gentamicin in neonates. Int J Pediatr 2017; 5 39 4575-4599
- 5 Dallos P, Wang C. Bioelectric correlates of Kanamycin Intoxication. Audiology 1974; 13 (04) 277-289
- 6 Garraghan F, Fallon R. Gentamicin : Dose regimens and monitoring. The Pharmaceutical Journal 2015; 295 7874/5 1-11
- 7 Ryan A, McGee TJ. Development of hearing loss in kanamycin treated chinchillas. Ann Otol Rhinol Laryngol 1977; 86 (2 pt. 1) 176-182
- 8 Kaloyanides GJ, Pastoriza-munoz E. Aminoglycoside nephrotoxicity.Kidney Int 1980; 18 (05) 571-582
- 9 Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngo 2011; Article ID 937861: 1-42
- 10 Cosgrove SE, Vigliani GA, Fowler VG. et al. Initial low- dose gentamicin for staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48 (06) 713-721
- 11 Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infec Dis N Am 2003; 17 (03) 503-528
-
12 PubChem Database, Gentamicin. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Gentamicin
- 13 Wellwood JM, Lovell D, Thompson AE. et al. Renal damage caused by Gentamicin: A study of the effects on renal morphology and urinary enzyme excretion. J Pathology 1976; 118 (03) 171-182
-
14 Product monograph, Gentamicin. 2017 Available at:https://www.baxter.ca/sites/g/files/ebysai1431/files/2018-11/Gentamicin_EN.pdf
- 15 Vučićević KM, Rakonjac ZM, Janković BZ. et al. Clinical pharmacokinetics in optimal Gentamicin dosing regimen in neonates. Central European Journal of Medicine 2014; 9 (03) pp 485-490
- 16 Idkaidek N, Arafat T. Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system. Mol Pharm 2012; 9 (08) 2358-2363
- 17 Ono C, Hsyu P-H, Abbas R. et al. Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: Prediction of drug–drug and drug–disease interactions. Drug Metabolism and Disposition 2017; 45 (04) 390-398
- 18 Hartmanshenn C, Scherholz M, Androulakis IP. Physiologically-based pharmacokinetic models: Approaches for enabling personalized medicine. Journal of Pharmacokinetics and Pharmacodynamics 2016; 43 (05) 481-504. doi:10.1007/s10928-016-9492-y
- 19 Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic(PBPK) models: A transition from academic curiosity to regulatory acceptance. Current Pharmacology Reports 216 2: 161-169. DOI: 10.1007/s40495-016-0059-9.
- 20 Abbiati RA, Manca D. A modeling tool for the personalization of pharmacokinetic predictions. Computers & Chemical Engineering 2016; 91: 28-37. doi:10.1016/j.compchemeng.2016.03.008
- 21 Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opinion on Drug Metabolism & Toxicology 2007; 3 (02) 235-249. doi:10.1517/17425255.3.2.235
- 22 Abduljalil K, Pan X, Pansari A. et al. Preterm physiologically based pharmacokinetic model. Part II: Applications of the model to predict drug pharmacokinetics in the preterm population. Clinical Pharmacokinetics 2020; 59 (04) 501-518
-
23 GmbH, B.T.S., Open Systems Pharmacology Suite., in PK-Sim. 2019 January 10,
Bayer Technology Services GmbH.
- 24 Contrepois A, Brion N, Garaud JJ. et al. Renal disposition of Gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemothe 1985; 27 (04) p 520-524
- 25 Willmann S, Lippert J, Schmitt W. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug MetabToxicol 2005; 1 (01) p 159-168
- 26 Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. Journal of Pharmaceutical Sciences 2005; 94 (06) 1259-1276
- 27 Ogubona F, Lawal A, Onyeji C. Saliva secretion of chloroquine in man. Journal of Pharmacy and Pharmacology 1986; 38 (07) 535-537
- 28 Willmann S. et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal of Pharmacokinetics and Pharmacodynamics 2007; 34 (03) p 401-431
- 29 Meunier F, Van der Auwera P, Schmitt H. et al. Pharmacokinetics of Gentamicin after IV infusion or IV bolus. J Antimicrob Chemother 1987; 19 (02) p 225-231
- 30 Valentin J. Basic anatomical and physiological data for use in radiological protection: Reference values: ICRP Publication 89. Annals of the ICRP 2002; 32 (3/4): p 1-277
- 31 Krishnan L, George S. Gentamicin therapy in preterms: A comparison of two dosage regimens. Indian Pediatr 1997; 34 p 1075-1080
- 32 European Medicines Agency. Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. 2016
- 33 Maharaj AR, Wu H, Hornik CP. et al. Pitfalls of using numerical predictive checks for population physiologically-based pharmacokinetic model evaluation. Journal of Pharmacokinetics and Pharmacodynamics 20169 46: 263-272
- 34 Soetaert K, Petzoldt T. Inverse modelling, sensitivity and monte carlo analysis in R using package FME. Journal of Statistical Software 2010; 33 (03) p 1-28
- 35 Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984; 104 (06) 849-854
- 36 Dorati Rossella, DeTrizio Antonella, Spalla Melissa. et al. Gentamicin Sulfate PEG-PLGA/PLGA-H Nanoparticles: Screening Design and AntimicrobialEffect Evaluation toward Clinic Bacterial Isolates. Nanomaterials 2018; 8 (01) 37
- 37 Bass KD, Larkin SE, Paap C. et al. Pharmacokinetics of once-daily Gentamicin dosing in pediatric patients. J Pediatr Surg 1998; 33 (07) p 1104-1107
- 38 Lee MG, Chen ML, Huang SM. et al. Pharmacokinetics of drugs in blood I. Unusual distribution of Gentamicin. Biopharmaceutics & Drug Disposition 1981; 2 (01) 89-97